Genome-wide association studies (GWASs) of major depressive disorder (MDD) have yet to identify variants that surpass the threshold for genome-wide significance. A recent study reported that runs of homozygosity (ROH) are associated with schizophrenia, reflecting a novel genetic risk factor resulting from increased parental relatedness and recessive genetic effects. Here, we explore the possibility of such a recessive model in MDD. In a sample of 9,238 cases and 9,521 controls reported in a recent mega-analysis of 9 GWAS we perform an analysis of ROH and common variants under a recessive model. Since evidence for association with ROH could reflect a recessive mode of action at loci, we also conducted a genome-wide association analyses under a recessive model. The genome-wide association analysis using a recessive model found no significant associations. Our analysis of ROH suggested that there was significant heterogeneity of effect across studies in effect (P ¼ 0.001), and it was associated with genotyping platform and country of origin. The results of the ROH analysis show that differences across studies can lead to conflicting systematic genome-wide differences between cases and controls that are unaccounted for by traditional covariates. They highlight the sensitivity of the ROH method to spurious associations, and the need to carefully control for potential confounds in such analyses. We found no strong evidence for a recessive model underlying MDD.
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INTRODUCTION
Major depressive disorder (MDD) is one of the leading burdens of disease in the world, with a lifetime prevalence of $15% [Kessler et al., 2003; Hasin et al., 2005] . It has been found to be moderately heritable, from 31% to 42% [Sullivan et al., 2000] , though with greater heritability in severe, recurrent forms of the disorder [McGuffin et al., 1996; Levinson, 2006] . A recent mega-analysis of nine genome-wide association studies found no significant associations with individual genetic variants (Psychiatric Genomics Consortium MDD Working Group, 2012), compared to $5 genome-wide significant associations in similar sized studies of other psychiatric disorders Sklar et al., 2011] . These association studies are conducted under an additive model, while the true effects of some risk variants may be recessive, for which individuals with two copies of an allele are at greater risk than would be predicted from twice a single allele's effect. In a fully recessive model only those with two copies of the risk allele are at risk, though there is also the possibility of partial recessive effects. As selection acts to remove deleterious alleles with respect to overall fitness from the population, genetic risk variants that are recessive can escape selection longer. Inbreeding within families (e.g. consanguineous marriages) often exposes such recessive alleles due to an increased likelihood of alleles at each locus being identical by descent. Until recently studies of inbreeding were focused on families or communities in which inbreeding is expressed relative to the founder generation, which is assumed to be unrelated and where inbreeding information was determined from self-reports or knowledge of pedigrees (pedigree inbreeding). For example, Rudan et al. [2003] found a higher incidence of six complex genetic diseases/disorders including MDD among Croatian villages with higher levels of pedigree inbreeding [Rudan et al., 2003] . By using genome-wide genotype data it is also possible to estimate an individual's inbreeding from more distant common ancestors to provide evidence for whether a recessive genetic model is more appropriate for a disorder.
One method to analyse the effect of inbreeding from genomewide genotype data is to identify segments of continuous homozygous SNPs, reflecting blocks of the genome that are identical by descent from a common ancestor. Runs of homozygosity (ROH) capture inbreeding effects that are due to common or rare causal variants better than a simple measure of excess number of homozygous SNPs across the genome, which tends to only capture the recessive effects of common variants . An association between percentage of genome covered by ROH (F ROH ) and schizophrenia has been reported [Keller et al., 2012] . Due to the possibility of genetic overlap between MDD and schizophrenia [Schulze et al., 2012 ; Cross-Disorder Group of the Psychiatric Genomics Consortium, 2013], a similar association between F ROH and MDD might be expected. However, MDD has a lower heritability (h 2 $ 0.37, Sullivan et al., 2000) than schizophrenia (h 2 $ 0.81, Sullivan et al., 2003) , which should attenuate genetic relationships. Moreover, some authors have suggested that MDD may not be under negative selection and the casual genetic variants may be beneficial in some circumstances [Nesse, 1999; Watson and Andrews, 2002; Belsky and Pluess, 2009; Power et al., 2013] . Here we look at the association between MDD and SNPs in 9,238 cases and 9,521 controls across nine studies (Table 1) [Psychiatric Genomics Consortium MDD Working Group, 2012] under a recessive genetic model. We also use genome-wide estimates of inbreeding to look for a consistent difference between cases and controls across nine studies of MDD, in order to support a recessive model of the disorder.
MATERIAL AND METHODS Sample
In this report, we analyzed individual data from the nine discovery samples [Ising et al., 2009; Sullivan et al., 2009; Lewis et al., 2010; Muglia et al., 2010; Rietschel et al., 2010; Shi et al., 2011; Shyn et al., 2011; Wray et al., 2012] of the PGC-MDD that together comprise 9,238 cases and 9,521 controls. Full sample details are given in the supplementary materials of the original analysis (Psychiatric Genomics Consortium MDD Working Group, 2012) , and are outlined in Table 1 . All subjects were of European ancestry (as determined from genome-wide genotypes). Cases were required to have diagnoses of DSM-IV lifetime MDD established using structured diagnostic instruments from direct interviews by trained interviewers (two studies required recurrent MDD and one recurrent, early-onset MDD) or clinician-administered DSM-IV checklists. Studies ascertained cases mostly from clinical sources, and controls were largely randomly selected from the population and screened for lifetime history of MDD.
Method of ROH Calling and Analysis
Genotyping was described in the supplementary materials in the original analysis (Psychiatric Genomics Consortium MDD Working Group, 2012). All samples were genotyped with single nucleotide polymorphism (SNP) arrays of greater than 200 K genome-wide SNPs, with analysis restricted to polymorphic SNP probes. In the original analysis, imputation to the CEU HapMap3 reference sample [Altshuler et al., 2010] , 1,235,109 autosomal SNPs, was performed using Beagle 3.0.4 [Browning and Browning, 2009] . In order to perform an association analysis under a recessive model or call runs of homozygosity (ROH), imputed SNP dosage data was converted to discrete genotype calls, keeping those SNPs with a probability of at least 0.95. The use of imputed SNPs helped to increase similarity of genomic coverage across studies. SNPs with a missingness of >2% or minor allele frequency (MAF) <5% were removed, as were then individuals with missingness over 2%. Prior to analysis SNPs were pruned for LD within PLINK, removing any SNPs with an R 2 0.90 with any other SNP in a 50 SNP window. The use of imputed data in ROH has previously been shown to give similar results to those restricting to only genotyped SNPs [Keller et al., 2012] . The calling of ROH and percentage of genome covered by ROH per individual (F ROH ) were derived within PLINK [Purcell et al., 2007] following the same method found to optimally detect effects of autozygosity, as described in Howrigan et al. [2011] . In particular, we used a series of sliding windows across the genome to call ROH within each individual separately. The size of the windows was set to 65 consecutive SNPs, so any single SNP would be found in 65 different windows. If at least four (>5%) of these windows contained entirely homozygous SNPs, then the SNP in question could be included within a ROH. Within windows, one missing SNP was allowed. To avoid false positives, only ROH with a minimum of 65 consecutive SNPs covering 2.3 Mb were used when calculating F ROH . In addition, the required minimum density in a ROH was set at 200 kb per SNP and the maximum gap between two consecutive homozygous SNPs was set at 500 kb. The estimate of the total genome captured was 2.77 Â 10 9 bp. The analysis was performed by study, using F ROH as a predictor of case-control status in a logistic regression. Percentage of SNPs missing, a SNP-by-SNP measure of homozygosity determined by PLINK's-het command, and the first five ancestry-informative principal components were used as covariates. The SNP-by-SNP measure of homozygosity was included to correct for differences in genomic-homozygosity levels unrelated to inbreeding, such as DNA quality or population ancestry. A mixed model was also examined combining all samples, using study as a random effect. This analysis was performed in STATA [StataCorp., 2011] . 
Genome-Wide Recessive Model
The genome-wide recessive model analysis used the autosomal dosage data converted to genotype calls as described above in the analysis of ROH. Analyses was performed in PLINK [Purcell et al., 2007] , using the-recessive command. The first five ancestry-informative principal components were included as covariates. Analysis was restricted to autosomes. Each study was analysed separately and then a meta-analysis was performed for each SNP across studies (using fixed effect P-value in PLINK). As the risk allele is set as the minor allele by default, and this may differ by study for alleles at frequencies near 0.5, we used the minor allele in the analysis of imputed data from the whole sample as a reference. A P-value <5 Â 10 À8 was considered as genome-wide significant. For this significance cut-off, we had 90% power to detect a relative risk of 1.47 for the rare recessive genotype for SNPs with a MAF from 0.3 to 0.5. However, power decreased rapidly for those alleles with lower MAF, with 90% power to detect those with a relative risk of 1.81 and MAF of 0.2, or with a relative risk of 2.21 and MAF of 0.15. For those SNPs with lower MAF, power reduced rapidly for a recessive model. Calculations were performed using CaTS Power Calculator [Skol et al., 2006] .
RESULTS
Across all samples the average percentage of the genome covered by ROH (F ROH ) was 0.11% (95% CI 0.102-0.112; Table 1), similar albeit slightly lower than average F ROH (0.15%) reported in an earlier report using the same parameters [Keller et al., 2012] . In our mixed model analysis across all samples with study as a random effect, we found no significant effect of F ROH on MDD status. However, there was substantial heterogeneity in direction of effect across studies (P ¼ 0.001, Fig. 1) . Overall, four studies showed increased F ROH in cases (one significantly, P ¼ 0.007), while five studies showed increased F ROH in controls (one where P ¼ 0.005). Including further principal components (up to 20) and increasing ROH size (up to 170 SNPs) made no difference to the heterogeneity of the results.
To explore this apparent heterogeneity we examined two features of the included studies that might provide insight into the results. The first issue was potential poor matching of cases and controls, which we tested within the combined RADIANT German and Bonn-Mannheim sample. Here cases were recruited from both of these two studies, whereas the controls were collected and genotyped only as part of the Bonn-Mannheim study. However, excluding the RADIANT cases and restricting to only the matched Bonn-Mannheim study's cases and controls still resulted in a significant association with ROH (P ¼ 0.03), as both sets of cases were found to have similar mean F ROH . This tentatively suggested that the heterogeneity apparent across studies was not replicated within studies recruited from the same geographic region. Secondly, we were interested in the effects of genomic coverage on ROH. Cases and controls from the Queensland Institute of Medical Research (QIMR) were recruited as one sample but included as two independent cohorts, based on their genotyping platform (Illumina 317k and 610k chips). When we restricted the analysis to only those SNPs directly genotyped on both platforms (202,062 SNPs), we found that the mean F ROH for the QIMR-610k sample reduced from 0.086% to 0.077%, compared to 0.078% for the QIMR-317k sample. This implies, as expected, that genotyping platform and genome coverage were influencing estimates of mean F ROH .
To better understand potential sources of heterogeneity in our findings, we used a linear meta-regression with a study's effect size as the outcome and features of the studies individually analysed as predictors. We tested percentage of cases with recurrent MDD, mean F ROH and genome-wide homozygosity, country of recruitment, presence of copy number variant probes on the platform, and genotyping platform as potential predictors of direction of effect (see Supplementary Table 1) . Genotyping platform was nominally associated with effect size (P ¼ 0.05), and the direction of effect of F ROH differed when studies on non-Illumina platforms were analysed separately. Within the three non-Illumina genotyped studies, increased inbreeding was protective against MDD (P ¼ 0.007) while within the six Illumina genotyped studies inbreeding was a significant risk factor for MDD (P ¼ 0.02). We noted that when more than one study was recruited from a country, the direction of effect for ROH was consistent across all studies recruited from the same country (see Fig. 1 ). However, this was only a significant predictor in the meta-regression when distinguishing between German and non-German studies (P ¼ 0.02). This level of confounding from genotyping and country likely reduced our power to detect a true effect of ROH and MDD.
FIG. 1. Beta coefficient from logistic regression of F ROH predicting MDD per study (with 95% CI, accounting for covariates).
Positive effects suggest that ROHs are a risk factor for MDD. Note that though no combined effect in the mixed model of the full sample, in Illumina studies increased F ROH was a risk factor (P ¼ 0.02) and in non-Illumina studies it was protective (P ¼ 0.007). Note also the consistency in studies from the same country:
Ã Australian studies; $ American studies; # German studies.
In the meta-analysis of a recessive model of association, 929, 138 SNPs were analysed, though not all appeared in all nine studies due to differences in genotyping coverage. The most significant recessive association was for rs13261582 on chromosome 8 in an intergenic region between SNTB1 and HAS2 (odds ratio of 2.0 for the minor A allele, MAF 0.22, P ¼ 2.58 Â 10 À6 ). However this SNP was only present in two studies (GenRED and STAR Ã D), and so is only supported by a subset of the sample. It did not appear among the reported top SNPs from the primary analysis of this dataset under an additive genetic model in the full sample (P ¼ 0.12). The results of the meta-analysis also showed a lower median P-value than expected by chance (l GC 0.97, see Supplementary Figs. 1 and 2 for Manhattan and QQ plots). The l GC was 1.03 for SNPs with MAF > 0.2 and 0.90 for SNPs with MAF < 0.2, implying smaller differences of genotype frequencies between cases and controls than expected by chance for SNPS with low MAF. This is possibly the result of the less accurate imputation of rare alleles, or a lack of power.
DISCUSSION
Our analyses show systematic differences in F ROH between cases and controls that differ in direction across studies. There are several explanations for these results, mostly highlighting limitations of this analysis. Firstly, we found systematic differences in mean F ROH between studies. This is not unexpected and likely reflects the density of the genomic coverage and the accuracy of imputation, since SNPs were restricted to those with high quality imputation. A similar level of variation in F ROH was observed in the Psychiatric GWAS Consortium's analysis of F ROH across 17 studies of schizophrenia [Keller et al., 2012] , though they did not report any heterogeneity of effect as a function of genotyping platform or country of recruitment. It seems unlikely that the heterogeneity of effect in the present study could be the result of differing SNP inclusion on the platforms, because such an explanation would imply systematic differences between cases and controls in the probability of homozygosity across SNPs as a function of platform. More likely in our opinion is the possibility that factors related to ascertainment of cases and controls differed across studies and influenced overall homozygosity. Such factors could include changes in homozygosity levels due to length and quality of DNA storage, or differences in ascertainment of cases and controls across populations. It is noteworthy that the two out of nine studies that genotyped controls independently of cases (GenRED and STAR Ã D) both showed higher F ROH in controls than cases. Further, studies appear to cluster by country of origin and direction of the effect of F ROH . All three German studies had increased F ROH in cases for example, while the two Australian and two US studies all showed increased F ROH in controls. This may reflect confounding demographic factors specific to each country. These unknown confounders, such as urban/rural status or religion, that influence both distant inbreeding (F ROH ) and MDD could explain the differences in effects between studies. A recent analysis of ROH and MDD in a partially overlapping sample of the GAIN study analysed here found exactly that. Religion confounded of the association due to reduced levels of depression but increased inbreeding in within the religious population of the Netherlands [Abdellaoui et al., 2013] . Certainly the initial hypothesis of this study, that an association with inbreeding would reflect negative selection on MDD and an excess of recessive causal mutations, seems an implausible explanation for the observed heterogeneity as the evolutionary cost of MDD status seems unlikely to have differed greatly among the ancestors of those included in the present study. Any of these explanations for the results of the F ROH analysis may give some insight into why the original mega-analysis of these nine studies did not lead to any replicable genome-wide significant findings.
Our results from the genome-wide association analysis of MDD also produced no evidence for a recessive model, failing to produce any genome-wide significant associations. It is possible that our underlying model of recessive effect is unsuitable for an outbred population. Here we looked at a recessive effect for the minor allele, but two alternate models may also have been viable: compound heterozygosity and overdominance. Compound heterozygosity is an additional risk in individuals carrying two recessive but nonidentical alleles within a genetic locus, while overdominance is the increased risk of homozygosity of any allele compared to being heterozygous. However, our analysis of both would have been restricted by low power and the use of biallelic markers, and were, therefore, not performed. Both the GWAS and ROH analyses suggest though that there is no underlying recessive model of MDD, at least not of large effect. Such an association was previously reported for schizophrenia in a similarly sized sample [Keller et al., 2012] , showing an increase of risk for schizophrenia by 17% for every additional percentage of the genome covered by ROH and was taken as evidence for historical selection against schizophrenia risk variants. The lack of a similar association here adds molecular evidence to that from epidemiological studies suggesting MDD has little impact on reproductive fitness compared to other psychiatric disorders, and so is under substantially less negative selection [e.g., Power et al., 2013] .
These results highlight that the analysis of F ROH appears to be sensitive to systematic differences between studies that are ostensibly unrelated to MDD status, potentially give rise to either false positive or false negative results. This suggests there are genome-wide differences in homozygosity and/or inbreeding between populations that are not corrected for by methods such as ancestry-informative principal components. We recommend the use of large combined samples in the analysis of F ROH as a predictor of traits and disorders, due to the high risk of spurious associations within one study. Preferably such analyses should be done with access to data on potential social and demographic confounders. One possible further improvement might be the development of novel methods for analysing ROH, particularly in imputed genotype data where probability for homozygosity across a region is available. As similar heterogeneity across studies was not seen in other analyses of ROH within consortia [Keller et al., 2012; McQuillan et al., 2012] , the significant heterogeneity in our results suggest that MDD is particularly sensitive to differing demographics in the ascertainment of cases and controls and this may present a problem to genome-wide polygenic approaches such as ROH. Certainly no strong evidence for a recessive model was apparent, supporting the view of MDD being under weaker negative selection than other psychiatric disorders. . Collection and quality control analyses of the control data set were supported by grants from NIMH and the National Alliance for Research on Schizophrenia and Depression. We are grateful to Knowledge Networks (Menlo Park, CA, USA) for assistance in collecting the control data set. We express our profound appreciation to the families who participated in this project, and to the many clinicians who facilitated the referral of participants to the study. (241944, 339462, 389927, 389875, 389891, 389892, 389938, 442915, 442981, 496675, 496739, 552485, 552498, 613602, 613608, 613674, 619667) , the Australian Research Council (FT0991360, FT0991022), the FP-5 GenomEUtwin Project (QLG2-CT-2002-01254) and the US National Institutes of Health (AA07535, AA10248, AA13320, AA13321, AA13326, AA14041, MH66206, DA12854, DA019951), and the Center for Inherited Disease Research (Baltimore, MD, USA). We thank the twins and their families registered at the Australian Twin Registry for their participation in the many studies that have contributed to this research. RADIANT was funded by: a joint grant from the UK Medical 
